StockNews.AI
ICU
StockNews.AI
148 days

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

1. SeaStar Medical will report Q4 and year-end 2024 results on March 27. 2. QUELIMMUNE, for pediatric AKI, was FDA approved in 2024. 3. SCD therapy has Breakthrough Device Designation for four indications. 4. Ongoing trial for SCD in adults with AKI impacts 200,000 annually.

Earnings
+1.38%Current Return
VS
+0.24%S&P 500
$2.1803/24 05:49 PM EDTEvent Start
$2.2103/26 12:09 AM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results could indicate growth post FDA approvals. Historical examples show higher stock valuations following successful trials and product launches.

How important is it?

The impending earnings announcement and product pipeline can influence investor perceptions. Positive results could further validate the company's growth strategy.

Why Short Term?

The immediate focus on March 27 results can lead to short-term volatility. Financial disclosures often drive market reactions quickly.

Related Companies

AKIFMSBCR
March 24, 2025 17:30 ET  | Source: SeaStar Medical DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT  Webcast:The live webcast and replay can be found here.  Conference ID:2078693  Dial-in numbers:1 (800) 715-9871 within the U.S.   1 (646) 307-1963 from outside the U.S.   A replay of the call will be available after 7:30 pm ET and can be accessed as follows: The webcast replay is available here.The call replay number is 1 (609) 800-9909 and will be available through April 3, 2025. About SeaStar Medical SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually. For more information visit www.seastarmedical.com or visit us on LinkedIn or X. Contact:SeaStar Investor Relations: IR@SeaStarMed.com

Related News